Phenotype Characteristics and Osteogenic Differentiation Potential of Human Mesenchymal Stem Cells Derived from Amnion Membrane (HAMSCs) and Umbilical Cord (HUC-MSCs)

Abstract

Introduction: Human amnion membrane mesenchymal stem cells (hAMSCs) and human umbilical cord mesenchymal stem cells (hUC-MSCs) are potential, non invasive sources of stem cells used for bone tissue engineering. Phenotyping characterization is an extremely important consideration in the choice of the appropriate passage in order to maximize its osteogenic differentiation potential. Aim: To explore phenotype characteristics and compare osteogenic differentiation potential of hAMSCs and hUC-MSCs. Method: Isolation and culture were performed on hAMSCs and hUC-MSCs from a healthy woman in her 38 th weeks of pregnancy. CD90, CD105 and CD73 phenotype characterization was done in passage 4-7. An osteogenic differentiation examination of hAMSCs and hUC-MSCs with Alizarin red staining and RUNX2 expression was performed in the passage that had appropriate expressions of phenotype characteristics. Results: The expression of CD90 hUC-MSCs was higher than that of hAMSCs in all passages. CD105 hUC-MSCs was higher in passage 4-6, while CD105 hAMSCs was equal to that of hUC-MSCs in passage 7. CD73 hUC-MSCs was higher than hAMSCs in passage 4 and 5, while in passage 6 and 7 hAMSCs was higher than hUC-MSCs. There was a decrease in the number of CD90, CD105 and CD73 on hAMSCs and hUC-MSCs in passage 5, then determined as appropriate passage. Alizarin red staining examination showed calcium deposition and revealed no significant difference, but RUNX2 expression of hUC-MSCs was significantly higher than that for hAMSCs. Conclusion: Both hAMSCs and hUC-MSCs had phenotype characteristics of mesenchymal stem cell and showed ostegenic differentiation potential.

Human adipose-derived mesenchymal stem cells inhibit proliferation and induce apoptosis of human gastric cancer HGC-27 cells

“…Mesenchymal stem cells (MSCs) can be obtained from umbilical cord, amniotic membrane, adipose tissue, and so on (Cho et al 2019;Han et al 2014;Hendrijantini and Hartono 2019;Zhang et al 2019). MSCs are usually used for the treatment of traumatic and degenerative diseases due to its extensive source, self-renewal potential, multi-lineage differentiation, and immunoregulatory ability (Li et al 2016).…”

Comparative Analysis of the Therapeutic Effects of Amniotic Membrane and Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Type 2 Diabetes

“…Although produced under the uniform and strict good manufacturing practice processes, MSCs are a heterogeneous population of cells from biological properties to therapeutic efficiency, highly depending on donor source, tissue origin, and cultural condition [ 2 , 39 ]. Despite originating from the same foetus, AMMSCs and UCMSCs could exhibit remarkable differences at diverse aspects including differentiation potential, paracrine factors and immunomodulatory capacity [ 21 – 24 , 40 ]. Human UCMSCs have been shown to proliferate faster than different donor-derived AMMSCs in serum-contained medium and chemically defined serum-free media [ 21 – 23 ].…”

Osteoinductive and Osteogenic Capacity of Freeze-Dried Bovine Bone Compared to Deproteinized Bovine Bone Mineral Scaffold in Human Umbilical Cord Mesenchymal Stem Cell Culture: An In Vitro Study

“…Isolation and culture of the hUCMSCs were done according to the method developed by Hendrijatini. 15 The umbilical cord was dissected into 1 cm pieces, and the umbilical arteries, veins, and adventitia were removed to obtain Wharton's jelly. Wharton's jelly was minced with a knife into 1 to 3 mm pieces and was used to isolate and culture primary hUCMSCs.…”

“…Characteristics of the harvested cells were confirmed with immunofluorescence by applying clusters of differentiation (CD) of CD34, CD 73, CD 90, and CD 105 as markers, according to the method suggested by Hendrijatini, 15 following the experimental protocol as follows: hUCMSCs were washed three times with PBS and then with a 1:100 dilution of primary antibodies from CD 45, CD 73, CD 90, and CD 105 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), which were added with fluorescein isothiocyanate (FITC)-conjugated antibodies. In addition, a total of 5 Â 10 5 cells were resuspended in 0.2 mL Phosphate Buffer Saline (PBS) and incubated with 10 µL of FITC-conjugated antibodies for 30 minutes at room temperature.…”